Home › Diffuse Scleroderma › Texas › Houston
Diffuse Scleroderma clinical trials in Houston, TX
5 studies for Diffuse Scleroderma are looking for participants at sites in and around Houston (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
RecruitingPhase 2
- Prolato Clinical Research Center, Houston
- Novel Research LLC, Bellaire · 7 mi away
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
RecruitingPhase 2
- EncompaSSc site in Houston, TX, Houston
Platform Clinical Study for Conquering Scleroderma
RecruitingPhase 2
- University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics, Houston
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
RecruitingPhase 1/2
- Nkarta Investigational Site, Houston
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
RecruitingPhase 2
- Artiva Investigational Site Bellaire, Bellaire · 7 mi away
Diffuse Scleroderma trials in other cities
- New York City, NY8 studies
- Chicago, IL7 studies
- Ann Arbor, MI7 studies
- Durham, NC6 studies
- Los Angeles, CA6 studies
- Baltimore, MD5 studies
- Boston, MA5 studies
- Philadelphia, PA4 studies
- Kansas City, KS4 studies
- Pittsburgh, PA4 studies
- New Orleans, LA4 studies
- Charleston, SC3 studies
Other studies in Houston
- Non-Small Cell Lung Cancer145 studies
- Breast Cancer126 studies
- Cancer (all types)123 studies
- Metastatic Cancer104 studies
- Colorectal Cancer102 studies
- Ovarian Cancer89 studies
- Acute Myeloid Leukemia86 studies
- Lung Cancer78 studies
- Prostate Cancer76 studies
- Endometrial Cancer68 studies
- Pancreatic Cancer62 studies
- Melanoma59 studies
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.